Cucurbitacin covalent bonding to cysteine thiols: The filamentous-actin severing protein Cofilin1 as an exemplary target

Cell Communication and Signaling

Volumn 11, Issue 1, 2013, Pages

  Gabrielsen, Mads ^a   Schuldt, Maike ^a   Munro, June ^a   Borucka, Dagmara ^a   Cameron, Jenifer ^a   Baugh, Mark ^a   Mleczak, Andrzej ^b   Lilla, Sergio ^a   Morrice, Nicholas ^a   Olson, Michael F ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

Actin; Cofilin; Cucurbitacin; Cytoskeleton

Indexed keywords

COFILIN 1; CUCURBITACIN; CUCURBITACIN D; CUCURBITACIN E; CUCURBITACIN I; CYSTEINE; DITHIOTHREITOL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CFL1 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG DETERMINATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ACTIN FILAMENT; MCF 7 CELL LINE; METABOLISM; CELL STRAIN MCF 7; PROTEIN BINDING;

ACTIN CYTOSKELETON; COFILIN 1; CUCURBITACINS; CYSTEINE; HUMANS; MCF-7 CELLS; PROTEIN BINDING;

EID: 84883083597     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-11-58     Document Type: Article

References (27)

1. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX, Nat Prod Rep 2005 22 386 399 10.1039/b418841c 16010347 (Pubitemid 40885718)
2. Cucurbitacin: ancient compound shedding new light on cancer treatment. Lee DH, Iwanski GB, Thoennissen NH, Sci World J 2010 10 413 418
3. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Chen X, Bao J, Guo J, Ding Q, Lu J, Huang M, Wang Y, Anticancer Drugs 2012 23 777 787 10.1097/CAD.0b013e3283541384 22561419
4. Triterpenoids for cancer prevention and treatment: current status and future prospects. Patlolla JM, Rao CV, Curr Pharm Biotechnol 2012 13 147 155 10.2174/138920112798868719 21466427
5. Cucurbitacins-a promising target for cancer therapy. Alghasham AA, Int J Health Sci 2013 7 77 89
6. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM, Cancer Res 2003 63 1270 1279 12649187 (Pubitemid 36348705)
7. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM, Oncogene 2005 24 3236 3245 10.1038/sj.onc.1208470 15735720 (Pubitemid 40695105)
8. Cucurbitacin B suppresses the transactivation activity of RelA/p65. Jin HR, Jin X, Dat NT, Lee JJ, J Cell Biochem 2011 112 1643 1650 10.1002/jcb.23078 21344491
9. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Chan KT, Li K, Liu SL, Chu KH, Toh M, Xie WD, Cancer Lett 2010 289 46 52 10.1016/j.canlet.2009.07.015 19700240
10. Cucurbitacin B inhibits 12-O-tetradecanoylphorbol 13-acetate-induced invasion and migration of human hepatoma cells through inactivating mitogen-activated protein kinase and PI3K/Akt signal transduction pathways. Zhou X, Yang J, Wang Y, Li W, Li-Ling J, Deng Y, Zhang M, Hepatol Res 2012 42 401 411 10.1111/j.1872-034X.2011.00933.x 22151918
11. Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma. Ahmed MS, Halaweish FT, J Enz Inhib Med Chem 2013 10.3109/14756366.2012.762646
12. Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells. Nakashima S, Matsuda H, Kurume A, Oda Y, Nakamura S, Yamashita M, Yoshikawa M, Bioorg Med Chem Lett 2010 20 2994 2997 10.1016/j.bmcl.2010.02.062 20347305
13. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Zhang T, Li J, Dong Y, Zhai D, Lai L, Dai F, Deng H, Chen Y, Liu M, Yi Z, Breast Cancer Res Treat 2012 135 445 458 10.1007/s10549-012-2175-5 22842972
14. Janus kinase 2 and signal transducer and activator of transcription 3 activation is not essential for CCL3-, CCL5- or CCL8-induced chemotaxis. Khabbazi S, Jacques RO, Moyano Cardaba C, Mueller A, Cell Biochem Func 2012 10.1002/cbf.2901
15. Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation. Ren S, Ouyang DY, Saltis M, Xu LH, Zha QB, Cai JY, He XH, Cancer Chemother Pharmacol 2012 70 415 424 10.1007/s00280-012-1921-z 22814677
16. The natural product cucurbitacin E inhibits depolymerization of actin filaments. Sorensen PM, Iacob RE, Fritzsche M, Engen JR, Brieher WM, Charras G, Eggert US, ACS Chemical Biol 2012 7 1502 1508 10.1021/cb300254s
17. Ecbalium elaterium (squirting cucumber)-remedy or poison? Raikhlin-Eisenkraft B, Bentur Y, Clin Toxicol 2000 38 305 308 10.1081/CLT-100100936 (Pubitemid 30397693)
18. Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. Knecht DA, LaFleur RA, Kahsai AW, Argueta CE, Beshir AB, Fenteany G, PLoS One 2010 5 14039 10.1371/journal.pone.0014039 21124831
19. Analysis of the human Cofilin1 structure reveals conformational changes required for actin-binding. Klejnot M, Gabrielsen M, Wood J, Mleczak A, Talapatra S, Kozielski F, Pannifer A, Olson MF, Acta Crystallogr D: Biol Crystallogr 2013 69 1780 1788 10.1107/S0907444913014418
20. Structure of the actin-depolymerizing factor homology domain in complex with actin. Paavilainen VO, Oksanen E, Goldman A, Lappalainen P, J Cell Biol 2008 182 51 59 10.1083/jcb.200803100 18625842 (Pubitemid 352008621)
21. Effect of cucurbitacins on bilirubin-albumin binding in human plasma. Greige-Gerges H, Abou Khalil R, Chahine R, Haddad C, Harb W, Ouaini N, Life Sci 2007 80 579 585 10.1016/j.lfs.2006.10.005 17097690 (Pubitemid 46043484)
22. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV, Gupta RC, Cancer Lett 2013 332 35 45 10.1016/j.canlet.2013.01.008 23340170
23. Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, Sakai T, Mol Nutr Food Res 2010 54 559 565 10.1002/mnfr.200900165 19937855
24. Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1. Lopez-Haber C, Kazanietz MG, Mol Pharmacol 2013 83 1141 1154 10.1124/mol.112.084293 23478800
25. Preparation and characterization of liposomes incorporating cucurbitacin E, a natural cytotoxic triterpene. Habib L, Khreich N, Jraij A, Abbas S, Magdalou J, Charcosset C, Greige-Gerges H, Int J Pharm 2013 448 313 319 10.1016/j.ijpharm.2013.03.027 23524087
26. p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival. Croft DR, Crighton D, Samuel MS, Lourenco FC, Munro J, Wood J, Bensaad K, Vousden KH, Sansom OJ, Ryan KM, Olson MF, Cell Res 2011 21 666 682 10.1038/cr.2010.154 21079653
27. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. Scott RW, Hooper S, Crighton D, Li A, Konig I, Munro J, Trivier E, Wickman G, Morin P, Croft DR, et al. J Cell Biol 2010 191 169 185 10.1083/jcb.201002041 20876278